Related Experiment Video
Updated: Jan 29, 2026
06:33
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
1.8K
Clofarabine for myelodysplastic syndromes.
Ramon V Tiu1, Fabiola Traina, Mikkael A Sekeres
1Taussig Cancer Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, Ohio, USA.
Expert Opinion on Investigational Drugs
|May 20, 2011
Summary
Clofarabine shows promise in treating myelodysplastic syndromes (MDS), with response rates up to 43%. While myelosuppression is a concern, this purine analog is generally well-tolerated and under investigation for MDS treatment.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myelodysplastic syndromes (MDS) have limited treatment options.
- Novel therapies are needed to improve response rates and survival in MDS.
- Clofarabine, a purine nucleoside analog, inhibits DNA biosynthesis and may affect DNA methylation.
Purpose of the Study:
- To review the efficacy and safety of clofarabine in treating myelodysplastic syndromes (MDS).
- To assess clofarabine's potential as a novel therapeutic agent for MDS.
Main Methods:
- A PubMed search was conducted for clofarabine in MDS and acute myeloid leukemia (AML) evolving from MDS.
- Included data from the 52nd Annual American Society of Hematology Meeting on response and safety.
Main Results:
- Clinical trials reported overall response rates of 31-43% in MDS and MDS/myeloproliferative neoplasms, including complete responders.
- Clofarabine demonstrated general tolerability in MDS patients, despite myelosuppression being a notable side effect.
Conclusions:
- Clofarabine shows potential as a treatment for MDS, with promising response rates.
- Further large-scale studies are necessary to confirm clofarabine's viability in MDS treatment.
- Intravenous clofarabine is available, and an oral formulation is under investigation for monotherapy or combination use.
Related Concept Videos
01:26Acute Coronary Syndrome V: Nursing Management
318
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
318
01:26Nephrotic Syndrome II : Assessment and Medical Management
237
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
237
01:24Nephrotic Syndrome I : Introduction
609
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
609
01:30Acute Coronary Syndrome I: Introduction
933
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
933
01:17Irritable Bowel Syndrome I: Introduction
996
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
996
01:27Restless Leg Syndrome and Night Terrors
535
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
535